Assay Shown to Help Detect Prostate Cancer Patients at Risk of Metastasis

Assay Shown to Help Detect Prostate Cancer Patients at Risk of Metastasis
An assay may help to determine those prostate cancer patients at risk of metastasis, a study reports. It works by  identifying a molecular subgroup of primary prostate cancer to detect patients who might have metastatic recurrence following radical prostatectomy. The study that validated the assay, “Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology,” was published in the Journal of European Urology. “An unbiased discovery approach was used to identify a molecular subtype of primary prostate cancer that demonstrated metastatic biology,” Richard Kennedy, vice president and medical director of Almac Group Diagnostics, which developed the assay, said in a news release. “This approach has created a very robust assay with excellent performance, independent of clinical factors such as Gleason and CAPRA," added Kennedy, who is also a professor of Medical Oncology at Queen’s University Belfast. "We believe it will play a significant role in aiding clinicians to select the most appropriate therapy regimen for their patients.” While prognosis for localized prostate cancer patients following radical prostatectomy is very good, evidence has shown that up to 25 percent of patients — dependent upon disease stage and use of population-based PSA screening — will develop metastatic disease within 15 years. The researchers used a molecular assay to identify a subg
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *